BioAge Labs, Inc. develops clinical-stage biopharmaceutical candidates for cardiometabolic diseases by targeting the biology of human aging. Its news centers on BGE-102, a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases, including diabetic macular edema.
Recurring updates cover Phase 1 biomarker and tolerability data, indication development for inflammation-driven disease, and research into long-acting injectable and oral small-molecule APJ agonists for obesity. BioAge also reports financial results, public offerings, R&D presentations, and collaborations that use its human longevity data platform to identify metabolic-aging pathways.
BioAge Labs (NASDAQ: BIOA), a clinical-stage biotech company focused on developing therapeutics for metabolic diseases through aging biology, has announced its participation in two major upcoming investor conferences. The company's leadership, including CEO and co-founder Dr. Kristen Fortney and CFO Dr. Dov Goldstein, will attend:
• The Jefferies Global Healthcare Conference in New York (June 3-5, 2025) for one-on-one meetings
• The Goldman Sachs 46th Annual Global Healthcare Conference in Miami (June 9-11, 2025), featuring a fireside chat on June 9 at 3:20 PM EDT and one-on-one meetings. A webcast will be available and archived for 30 days on the company's investor relations website.
BioAge Labs (BIOA) reported its Q1 2025 financial results and business updates, highlighting progress in its metabolic disease therapeutics pipeline. The company's lead candidate BGE-102, an oral brain-penetrant NLRP3 inhibitor for obesity, is advancing with initial Phase 1 data expected in H2 2025. BioAge announced a strategic collaboration with Lilly ExploR&D to develop therapeutic antibodies and continues to advance its APJ agonist program for obesity.
Financial results show R&D expenses increased to $11.1 million from $9.3 million YoY, while G&A expenses rose to $6.8 million from $3.5 million. The company reported a net loss of $12.9 million ($0.36 per share). BioAge maintains a strong financial position with $335.1 million in cash and equivalents, expected to fund operations through 2029.
BioAge Labs (BIOA) reported its full year 2024 financial results and Q4 business updates. The company discontinued its STRIDES Phase 2 trial of azelaprag due to unexpected liver issues but continues developing next-generation APJ agonists for obesity. BGE-102, their oral brain-penetrant NLRP3 inhibitor, was nominated as a development candidate with Phase 1 data expected in 2H25.
The company secured strategic collaborations with Novartis ($20M upfront plus up to $530M in milestones) and Lilly for novel therapeutic development. Financial results showed R&D expenses of $59.0M (up from $33.9M in 2023) and G&A expenses of $19.2M (up from $14.5M). Net loss was $71.1M or $6.63 per share.
BioAge maintains a strong financial position with $354.3M in cash, expected to fund operations through 2029.
BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company focused on developing therapeutic products for metabolic diseases through aging biology, has announced its participation in TD Cowen's 45th Annual Health Care Conference.
The conference is scheduled for March 3-5, 2025, at the Boston Marriott Copley Place in Boston, MA. BioAge will engage in one-on-one meetings during the event, which features presentations, fireside chats, and panel discussions moderated by TD Cowen research team members, covering various healthcare industry aspects.
BioAge Labs announced significant updates to its clinical programs and platform development. The company has discontinued azelaprag development due to liver transaminitis observations in the STRIDES Phase 2 obesity trial, but is advancing next-generation APJ agonists with a development candidate expected by end of 2025.
The company nominated BGE-102, a brain-penetrant NLRP3 inhibitor, as a development candidate for neuroinflammation conditions, with Phase 1 SAD data expected by end of 2025. BioAge also expanded its discovery efforts through collaborations with Novartis (worth up to $550 million) and Lilly ExploR&D for antibody therapeutics development.
Financially, BioAge reported $334.5 million in cash and equivalents as of September 30, 2024, plus $27.6 million from IPO greenshoe exercise, extending runway beyond 2029.
BioAge Labs has announced a multi-year research collaboration with Novartis to discover novel therapeutic targets for age-related diseases. The partnership combines BioAge's human longevity datasets with Novartis's expertise in exercise biology. Financial terms include up to $20M in upfront payments and research funding, plus potential future milestones of up to $530M.
BioAge's platform leverages longitudinal human aging cohorts tracked for up to 50 years, using advanced analytics and machine learning to identify determinants of healthy lifespan. Both companies will have rights to advance discovered targets and receive reciprocal success milestones and tiered royalties.
BioAge Labs (BIOA) has announced the discontinuation of its STRIDES Phase 2 clinical trial evaluating azelaprag in combination with tirzepatide for obesity treatment. The decision follows observations of liver transaminitis in some subjects receiving azelaprag, though without clinically significant symptoms. The study, which enrolled 204 subjects, was designed to evaluate two oral doses of azelaprag combined with tirzepatide in individuals aged 55 and older with obesity.
The company will analyze available data from enrolled subjects and plans to share updated plans for azelaprag in Q1 2025. In parallel, BioAge continues advancing its pipeline, including a brain-penetrant NLRP3 inhibitor program targeting neuroinflammation, with IND submission anticipated in second half of 2025.
BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company focused on developing therapeutics for metabolic diseases through aging biology, has announced its participation in the Goldman Sachs Second Annual "Year-Ahead" Catalyst Clinic. The presentation is scheduled for Thursday, December 19, 2024, from 11-12 PM EST.
The event will feature a virtual presentation that will be accessible via webcast. Interested parties can access the live presentation through registration, and replays will be available on the company's investor relations website for 30 days following the event.
BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company focused on developing therapeutics for metabolic diseases through aging biology, has announced its participation in two major healthcare conferences. Kristen Fortney, CEO and co-founder, will present at the Piper Sandler 36th Annual Healthcare Conference in New York on December 3, 2024 (1:30-1:55 PM EST) and the Citi 2024 Global Healthcare Conference in Miami on December 4, 2024 (3:15-3:55 PM EST). Both presentations will be available via webcast and archived for 30 days on the company's investor relations website.